Earnings release
Page 1
RNS Number : 6706SInspiration Healthcare Group PLC12 February 2026 Inspiration Healthcare Group plc("Inspiration Healthcare", the "Company" or the "Group") Full year trading update Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company pioneering best-in-class,specialist neonatal intensive care medical devices, provides its unaudited trading update for year ended 31January 2026 ("FY26"). Highlights · Strong H2 trading performance, with revenue of £23.5 million, up 10.3% year-on-year (H2 FY25: £21.3 million) · FY26 revenue growth of 24.0% to £47.5 million (FY25: £38.3 million) · Adjusted EBITDA in line with current consensus market expectations1 · Good sales momentum expected to continue into FY27 with a solid pipeline of opportunities · New multi-year purchasing agreement signed with one of the largest hospital networks in the United States · Net debt reduced 39% to £5.1 million at 31 January 2026 (31 January 2025: £8.3 million) Revenue for the year increased by approximately 24% to £47.5 million (FY25: £38.3 million), slightly ahead ofconsensus market expectations, following a strong H2 performance across the Group. Adjusted EBITDA isexpected to be in line with market consensus, as a result of sales mix effects. Progress continues under theGroup's 'Back to Basics' strategy, with stronger operational execution leading to an improved sales outlook,growing profits, positive cash flow and reducing net debt. SLE, our global leader in neonatal ventilation, delivered a strong performance in H2 exceeding managementexpectations, following the re-alignment of the Group's branding. With local distributor managers now in placein Southeast Asia and Latin America, SLE is well positioned to re-establish its international position which willsupport the Group's growth strategy. At the end of FY26, the Company announced a significant three-year purchasing agreement with one of thelargest hospital networks in the United States, through its subsidiary in Florida, Airon Corporation ("Airon"). Thisagreement includes an initial order for 150 units for its Model A and Neo ventilators and accessories,representing a meaningful expansion to its installed base in the US. This contract establishes a high-quality,long-term revenue stream for Airon and directly supports Inspiration Healthcare's strategic objective ofdoubling Airon revenue within five years. In addition to initial equipment sales, the agreement includesexpectations for ongoing consumables and service revenue, which has the potential to substantially increasethe lifetime value of the partnership. At 31 January 2026, the Group's net debt (excluding IFRS16 lease liabilities) was £5.1 million a reduction of 39%(£3.2 million) over the year with the Group achieving significant reductions in inventory and receivables underits 'Back to Basics' strategy. 1 Current consensus market expectations for FY26 revenue and adjusted EBITDA are £44.1 million and £2.8million respectively. Raffi Stepanian, CEO of Inspiration Healthcare, said: "FY26 represents a year of good progress for InspirationHealthcare, with full year revenues increasing to £47.5 million and adjusted EBITDA expected to be in line withmarket expectations. We saw a strong performance across the Group, which combined with disciplined execution ofour 'Back to Basics' strategy, has driven a return to growth in our international markets, improved profitability andreduced net debt. "Our refreshed strategy with three business units: SLE for neonatal ventilation globally, Inspiration Healthcare as amedtech distribution channel in the UK and Ireland, and Airon as global leader in pneumatic ventilation is fullyimplemented. With increased focus on gaining share in Europe, increasing recurring revenues from consumables andservice, we are taking important steps towards higher quality revenue streams complementing the revenue fromcapital sales. We ended the year with encouraging sales momentum and a robust pipeline, providing confidencewithin the team as we look ahead to FY27." For further information, please contact: Inspiration Healthcare Group plc Tel: +44 (0)330 175 0000Raffi Stepanian, Chief Executive OfficerAlan Olby, Chief Financial Officer Panmure Liberum (Nominated Adviser & Broker) Tel: +44 (0)20 3100 2000Will GoodeEmma EarlMark Rogers
Page 2
Cavendish Capital Markets (JointBroker) Tel: + 44 (0)20 7220 0500 Giles Balleny / Joe SmithNigel BirksHarriet Ward Walbrook PR Ltd (Media &IR) Tel: +44 (0)20 7933 8780 or inspirationhealthcare@walbrookpr.com Anna Dunphy Mob: +44 (0) 7876 741 001Rachel Broad Mob: +44 (0) 7747 515 393 About Inspiration Healthcare Inspiration Healthcare (AIM: IHC) designs, manufactures and markets pioneering medical technology. Based inthe UK, the Company specialises in neonatal intensive care medical devices, which are addressing a critical needto help to save the lives and improve the outcomes of patients, starting with the very first breaths of life. The Company has a broad portfolio of its own products and complementary distributed products, for use inneonatal intensive care designed to support even the most premature babies throughout their hospital stay. Itsown branded products range from highly sophisticated capital equipment such as ventilators for life supportthrough to single-use disposables. The Company sells its products directly to hospitals and healthcare providers in the UK and Ireland, where it alsodistributes a range of advanced medical technologies for infusion therapy. In the rest of the world the Companyhas an established network of distribution partners around the world giving access to more than 75 countries. The Company operates in the UK from its world-class Manufacturing and Technology Centre in Croydon, SouthLondon and in the USA from its facility in Melbourne, Florida. Further information on Inspiration Healthcare can be found at www.inspirationhealthcaregroup.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authorityto act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this informationmay apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the informationcontained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. Forfurther information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END